– USA, TX – Mirna Therapeutics, Inc. (Nasdaq:MIRN), a clinical-stage biopharmaceutical company developing a broad pipeline of microRNA-based oncology therapeutics, today announced the appointment of Peter Greenleaf to the Company’s Board of Directors. Mr. Greenleaf brings over 20 years of experience in drug development and commercialization and currently serves as the Chairman and Chief Executive Officer of Sucampo Pharmaceuticals, Inc. (Nasdaq: SCMP), a global biopharmaceutical company.
“We are pleased to welcome an executive with Peter’s extensive senior leadership experience to our Board of Directors,” said President and CEO Paul Lammers, M.D., M.Sc. “His expertise driving the evolution of early-stage research to product development and commercialization will be invaluable as we advance our pipeline of microRNA-based oncology therapeutics.”
Prior to joining Sucampo, Mr. Greenleaf served as CEO and a board member at Histogenics Corporation, a regenerative medicine company. Previously, he served as President of MedImmune LLC, the global biologics arm of AstraZeneca, where he led the expansion of MedImmune’s pipeline to over 120 clinical and preclinical programs, and the commercialization of its marketed products.
“I am delighted to join the Board of Mirna Therapeutics, a pioneer in the emerging field of microRNA-based therapies,” said Mr. Greenleaf. “And I look forward to working with the Board and management on Mirna’s strategy and growth initiatives in the years ahead.”
Mr. Greenleaf is a member of the Board of Directors of Mast Therapeutics, Inc. (NYSE MKT: MSTX). Additionally, he is a member of the Board of Directors of the Pharmaceutical Research and Manufacturers of America (PhRMA) and Biotechnology Industry Organization (BIO), for which he serves on the Governing Boards of the Emerging Companies Section and the Health Section. Mr. Greenleaf earned a bachelor’s degree from Western Connecticut State University and a master’s degree in business administration from St. Joseph’s University.
About Mirna Therapeutics, Inc.
Mirna is a clinical-stage biopharmaceutical company developing a broad pipeline of microRNA-based oncology therapeutics and is the first to establish clinical proof-of-concept for a microRNA replacement therapy for cancer. Mirna’s lead product candidate, MRX34, a mimic of naturally occurring microRNA-34 (miR-34), is currently being studied in a Phase 1 clinical trial in patients with primary liver cancer, advanced solid tumors and hematological malignancies. miR-34 is one of the most widely published microRNAs and is considered a key regulator of multiple oncogenes across key oncogenic pathways, with the capacity to regulate more than 30 different oncogenes and repress the immune checkpoint signaling molecule PD-L1. The potential capacity to simultaneously affect multiple pathways and processes that are critical to cancer cell viability may make mimics of tumor suppressor microRNAs potent anti-cancer agents and less susceptible to drug resistance. Mirna plans to develop MRX34 as a monotherapy and in combination with other therapeutic modalities, such as targeted therapies and immuno-oncology agents. The company was founded in 2007 and is located in Austin, Texas.
- Disclaimer - News, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.
Comments are closed.